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MinireviewMcBindall—A Better Name for
CCAAT/Enhancer Binding Proteins?
code a heterodimeric transcription factor, as well as
recognition that the Myc proto-oncogene encodes a
transcription factor. Such studies also provided a frame-
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work and powerful battery of reagents useful for the5323 Harry Hines Boulevard
biological study of C/EBP itself. Finally, biochemicalDallas, Texas 75390
studies of C/EBP helped dispel the myth, anticipated
from earlier work on bacterial gene expression, that
eukaryotic transcription factors must have exquisiteC/EBP-related transcription factors regulate the bal-
binding specificity. This shift of thinking led to the under-ance between cell proliferation and mitotic growth ar-
standing that eukaryotic genes employ complex en-rest during terminal differentiation. Three new studies
hancers that integrate the instruction of multiple tran-give evidence that this regulation is mediated by pro-
scription factors acting in a combinatorial mannertein:protein interactions completely distinct from the
(Thompson and McKnight, 1992).role of C/EBPs in gene expression.
The previous issue of Cell and the most recent issue
of Molecular Cell present three exciting papers relevantIn the mid-1980s Barbara Graves and Peter Johnson
to the function of various members of the C/EBP familywere postdoctoral fellows in my laboratory at the Carne-
of transcription factors. What readers will see from thesegie Embryology Department. Barbara and Peter were
new discoveries is that the term McBindall may indeedworking to purify what they believed to be two indepen-
have been far superior to the silly acronym that I continuedent transcription factors isolated from rat liver tissue.
to wear around my neck like a rotting albatross. NotBarbara was chasing an activity designated CCAAT
only do these transcription factors bind to a variety ofbinding protein (CBP) by use of a DNaseI footprinting
different cis-regulatory DNA sequences, but they alsoassay that monitored binding of the protein to a cis-
bind and control the activity other key regulatory pro-regulatory sequence common to many promoters tran-
teins—some having nothing to do with gene expression!scribed by RNA polymerase II. Using similar methods,
Before turning to this new and exciting work a bitPeter was on the trail of an activity called enhancer
more history is useful. In thinking about the biologicalbinding protein (EBP) that bound with high affinity to the
role of the founding member of the C/EBP family—nowenhancer core element common to the transcriptional
designated C/EBP—we were most influenced by itsenhancers of SV40, murine sarcoma virus, and poly-
pattern of cell-type distribution as assessed by the useomavirus. Much to the chagrin of Barbara and Peter, as
of high-affinity antibodies. Immunohistochemical stain-the two efforts matured, the CBP and EBP activities
ing revealed C/EBP expression limited to the fully dif-copurified—all the way down to a single polypeptide
ferentiated cells of the tissues in which it was expressed(Graves et al., 1986; Johnson et al., 1987). My attitude
(liver, gut, adipose, skin, mammary gland, etc.). More-of inveterate optimism gave the following spin—if this
over, in the 3T3-L1 model of terminal adipogenesis,single DNA binding protein were capable of binding both
C/EBP was observed to be absent in undifferentiatedof the most celebrated cis-regulatory elements associ-
preadipocytes, yet copiously expressed in fully differen-ated with RNA polymerase II promoters and enhancers,
tiated, fat-laden adipocytes (Birkenmeier et al., 1989).the activity simply had to be of huge biological rele-
These clues led to the idea that C/EBP might be in-vance. Barbara and Peter were more sanguine and level
volved in specification of either mitotic growth arrest,headed, realizing that this enigmatic DNA binding activ-
terminal differentiation, or both. In the ensuing 15 years,
ity was breaking one of the cardinal rules of gene-spe-
extensive and articulate studies of C/EBP in a variety
cific transcription factors. Instead of binding DNA with
of experimental settings have provided compelling evi-
high specificity, it was equally adept in the recognition dence favoring its role in both growth arrest and termi-
of apparently unrelated substrates. It was in that setting nal differentiation. In the former case, Umek and col-
that, behind my back, Barbara and Peter began referring leagues prepared a stable cell line expressing a chimeric
to this activity as either McBindall or McScription factor. C/EBP-estrogen receptor fusion protein. Exposure of
With a bit of arm-twisting, Graves and Johnson were these cells to estradiol led to cessation of mitotic growth
OK with a new name for the factor—C/EBP (CCAAT/ (Umek et al., 1991). In the latter case, Lane and col-
enhancer binding protein). More importantly, with the leagues conducted both loss-of-function and gain-of-
help of Bill Landschulz, they were convinced to continue function experiments consistent with the essential role
the task of purification and identification of the relevant of C/EBP in the terminal differentiation of cultured 3T3-
polypeptide, culminating with the cloning of a cDNA L1 preadipocytes (Lin and Lane 1992, 1994). Both of
copy of its encoding gene (Landschulz et al., 1988). In these fundamental interpretations derived from cell cul-
retrospect I trust that Graves, Johnson, and Landschulz ture experimentation have been rigorously confirmed by
are proud of their efforts. Studies of C/EBP led to the the C/EBP gene knockout studies of Darlington and
discovery of the leucine zipper (bZIP) and basic helix- colleagues (Wang et al., 1995).
loop-helix (bHLH) categories of transcription factors, the Finally, it is notable that mammals encode two addi-
recognition that the Fos and Jun proto-oncogenes en- tional transcription factors highly related to C/EBP—
designated C/EBP and C/EBP. The bZIP DNA binding
domains of the three proteins are exceedingly similar in1Correspondence: smckni@biochem.swmed.edu
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primary amino acid sequence. Despite this similarity, logic, and theory in biology always take a back seat to
experimentation. One would never have guessed thatevidence has accumulated indicating that the latter iso-
forms may be functionally distinct from C/EBP when a transcription factor would mediate growth arrest via
circuitry having nothing to do with gene expression!viewed from a biological perspective. Although all three
proteins bind DNA as homodimeric transcription factors Not being enough that C/EBP evolved a means of
inhibiting cyclin:cdk interaction, Porse and colleaguesin a nearly indistinguishable manner, they are expressed
with quite distinct temporal kinetics as a function of report the critical nature of C/EBP as a repressor of
E2F in the terminal differentiation of adipocytes andterminal cell differentiation. In the 3T3-L1 model of termi-
nal adipocyte differentiation, C/EBP and C/EBP are granulocytes (Porse et al., 2001 [October 19 issue of
Cell]). Recently published studies from Slomiany andexpressed during the early, clonal expansion phase of
adipogenesis. Subsequent to this period of aggressive Johansen gave evidence of direct repression of E2F-
dependent transcription by C/EBP (Slomiany et al.,mitotic cell growth, C/EBP and C/EBP expression lev-
els diminish acutely and come to be replaced by C/EBP 2000; Johansen et al., 2001). Porse and colleagues re-
port the generation of laboratory mice bearing lesions(Cao et al., 1991). Yeh and colleagues have provided
evidence that this temporal cascade of C/EBP isoform in the C/EBP polypeptide that eliminate E2F repres-
sion, yet leave intact C/EBP’s ability to bind DNA andexpression lies at the heart of both the proliferative and
maturational phases of adipogenesis (Yeh et al., 1995). activate its conventional array of target genes. Consis-
tent with in vitro studies showing that these E2F repres-How is it that certain isoforms of the C/EBP family
favor mitotic growth, whereas another exerts an antago- sion-deficient forms of C/EBP are incapable of sup-
pressing mitotic proliferation, mice bearing similarlynistic influence? Here we are able to turn to three new
papers that delve into the precise mechanisms by which impaired forms of C/EBP were found to be deficient
in the terminal differentiation of adipocytes and granulo-C/EBP isoforms differentially regulate mitotic cell
growth. Two of these papers provide evidence relevant cytes. Such studies provide compelling evidence that
E2F repression by C/EBP is critical for its ability toto the means by which C/EBP causes mitotic growth
arrest. The third paper shows how phosphorylation of induce terminal differentiation, and further establish a
concrete interpretation of the means by which a lineage-C/EBP leads to cell survival under conditions of liver
regeneration. instructive transcription factor can couple growth arrest
to differentiation.Thanks to the magical work of Hartwell, Nurse, Matsui,
Mahler, Hunt, Ruderman, and scores of others— Is C/EBP a tumor suppressor gene? The answer to
this question came as a resounding yes from the recentrecognized just this week by our paragons in Stock-
holm—we understand the regulatory apparatus respon- work of Tenen and colleagues (Pabst et al., 2001). By
use of standard molecular biological approaches, Tenensible for controlling the cell division cycle. In brief, a
protein kinase designated cdk2 must be activated in discovered dominant-negative mutations in the human
gene encoding C/EBP in acute myeloid leukemias. p53order for cells to move their way through mitosis. Activa-
tion of cdk2 falls under the regulation of the famous this is not. On the other hand, these incipient, human
genetic studies do provide evidence favoring the validitycyclin polypeptides, whose levels ebb and flow under
careful regulation at the levels of both synthesis and of scientific interpretations of C/EBP function as stud-
ied in model systems.degradation. Given the antimitotic activity of C/EBP,
any discerning scientists would happily consider the Saving the best for last, we now turn to the work
of Buck and colleagues on C/EBP (Buck et al., 2001idea that this transcription factor might regulate cell
cycle progression by controlling the transcription of one [October issue of Molecular Cell]). Recall that C/EBP,
unlike C/EBP, is expressed in proliferative cells—ator more of the genes encoding the master regulatory
polypeptides (cyclins, cdks, etc.). No, this is not at all least as studied in cell culture systems of terminal differ-
entiation (Cao et al., 1991; Yeh et al., 1995). The Buckhow things work. Wang and colleagues instead show
that a short region of the C/EBP polypeptide interacts study started with a model for hepatic injury. Under such
conditions, including exposure to carbon tetrachloride,directly with the cdk2 and cdk4 enzymes in a manner
that prevents cyclin binding (Wang et al., 2001 [October hepatic stellate cells produce excessive fibrous tissue
leading to cirrhosis. It was observed that carbon tetra-issue of Molecular Cell]). This inhibitory interaction is
completely independent of the DNA binding domain of chloride induces activation of the RSK protein kinase,
which in turn leads to stellate cell proliferation and phos-C/EBP and maps to a region of the polypeptide totally
distinct from the region that—as will be articulated sub- phorylation of threonine 217 of C/EBP. By contrast,
the same treatment of C/EBP-deficient mice causedsequently—leads to E2F repression. On its own, this
short region of C/EBP can inhibit cdk’s in living cells, stellate cells to suffer programmed cell death. Remark-
ably, mice bearing a threonine-to-alanine mutation atresulting in growth arrest. Finally, hepatocyte extracts
derived from C/EBP knockout mice contain elevated residue 217 of the C/EBP polypeptide respond to liver
injury in the same manner as C/EBP-deficient animals.cdk levels. Going back to the original Umek paper de-
scribing C/EBP-mediated growth arrest, it was shown What is so important about phosphorylation of threo-
nine 217 of C/EBP? Buck and colleagues argue thatthat the amino-terminal region—now known to inhibit
cyclin interaction with cdks—is essential for growth ar- this modification creates a functional XEXD caspase
substrate inhibitor. KphosphoTVD is interpreted to formrest (Umek et al., 1991). At that time the most logical
interpretation was that the amino-terminal region repre- an active caspase inhibitor/substrate—which could be
mimicked by a gain-of-function allele of C/EBPwhereinsented an essential domain of the transcription factor
in the context of its role in gene regulation. Here we offer threonine 217 was changed to glutamic acid. Finally,
Buck and colleagues provide evidence that hepatic stel-students an important lesson in biology—parsimony,
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late cells derived from C/EBP-deficient and C/EBP-
ala217 mice can be rescued from programmed cell
death by treatment with the cell permeant KE217VD pep-
tide or a C/EBP-glu217 expression vector. What does
this all mean? Taken most literally, the data of Buck and
colleagues say that RSK-mediated phosphorylation of
threonine 217 of the C/EBP transcription factor consti-
tutes a critical event allowing stellate cells to evade
programmed cell death upon liver injury. This has noth-
ing whatsoever to do with the role of C/EBP as a tran-
scription factor—but represents a literal life-or-death
reaction for stellate cells.
Are these “out of the box” activities of C/EBP polypep-
tides baroque exceptions to our ordering thinking that
gene products have evolved to efficiently accommodate
highly individualized tasks? By contrast, are we instead
seeing the tip of an unanticipated iceberg? Might it be
that biological reactions and pathways are far more in-
terwoven than one would logically anticipate? If so,
chalk one more point up for the experimentalists. The
smartest theoretician—even if qualified as a card-car-
rying “nonlinear thinker”—could never have predicted
the outcomes we now so pleasurably contemplate.
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